Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled Trial of CX516 (Ampakine) Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia

NCT00235352 is registered in ClinicalTrials.gov with North Suffolk Mental Health Association as lead sponsor.

NCT NCT00235352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00235352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled Trial of CX516 (Ampakine) Added to Clozapine, Olanzapine or Risperidone in Patients With Schizophrenia
Lead sponsor
North Suffolk Mental Health Association
Phase
Phase 2/3
Overall status
Completed
Start date
February 28, 2002
Completion date
February 28, 2007
Enrollment
105 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia